CytRX Corporation

CytRx Corporation, a biopharmaceutical research and development company, specializes in oncology. Its drug development pipeline includes INNO-206, which is in Phase Ib clinical trial and is completing Phase Ib/II clinical trial for the treatment for soft tissue sarcomas; and tamibarotene that in Phase IIb clinical trial for the treatment of non-small-cell lung cancer and is in a clinical trial as a treatment for acute promyelocytic leukemia.

Ticker:
CYTR
Exchange:
NASDAQ (See More NASDAQ Companies)
Sector:
Healthcare (See More Healthcare Companies)